Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q13144

UPID:
EI2BE_HUMAN

ALTERNATIVE NAMES:
eIF-2B GDP-GTP exchange factor subunit epsilon

ALTERNATIVE UPACC:
Q13144; Q541Z1; Q96D04

BACKGROUND:
eIF-2B GDP-GTP exchange factor subunit epsilon is crucial for the initiation phase of protein synthesis, facilitating the exchange of GDP for GTP on eukaryotic initiation factor 2. This process is vital for the regulation of translation, affecting cell growth and stress responses.

THERAPEUTIC SIGNIFICANCE:
Mutations affecting this protein cause Leukoencephalopathy with vanishing white matter 5, characterized by neurological decline, cerebellar ataxia, and in some cases, ovarian dysfunction. The connection between this protein and the disease highlights the importance of research into its functions and mechanisms, paving the way for innovative treatments for leukoencephalopathy and potentially other related conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.